Llwytho...
Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma
MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88(L265P) alone may not be sufficient to induce tumor formation. Interplay between MYD88(L265P) and other genetic events is further supported by the fact that TNFAIP3 (A2...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood Cancer J |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group UK
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6177394/ https://ncbi.nlm.nih.gov/pubmed/30301877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0130-3 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|